AMGN

#80
Amgen Inc. - Common Stock
335.5 8 USD
-0.27%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
334.47
335.65
年范围
267.83
391.29
日变化
-0.27%
每月变动
-1.52%
6个月变化
-2.23%
年变化
+18.43%
前一天收盘价
336.4 8
Open
334.9 2
最低价
334.4 7
High
335.6 5
交易量
777
展开完整图表 完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 181.12 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry 药品制造—常规
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
24.49
市销率
5.13
每股股息
2.52
股息收益率 %
2.79

Amgen Inc. - Common Stock

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

新闻